Showing results (91-100 of 134) with videos related to
Sort By:
Pageof 14
Journal of Clinical Microbiology|February 3, 2000
Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapyL Stuyver, C Van Geyt, S De Gendt, et al.Journal of Gastroenterology and Hepatology|January 22, 2003
Animal models for the study of HBV infection and the evaluation of new anti-HBV strategiesF Zoulim, P Berthillon, F L E Guerhier, et al.Antimicrobial Agents and Chemotherapy|February 1, 1996
2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivoF Zoulim, E Dannaoui, C Borel, et al.Journal of Viral Hepatitis|June 16, 2015
T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patientsQ Wang, P Sachse, M Semmo, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 6, 2018
Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemiaP Miailhes, K Hartig-Lavie, V Virlogeux, et al.Journal of Viral Hepatitis|March 12, 2014
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease scoreV Virlogeux, P Pradat, F Bailly, et al.Journal of Viral Hepatitis|June 23, 2011
Adefovir serum levels do not differ between responders and nonrespondersK Deterding, L Naesens, M Buti, et al.Antimicrobial Agents and Chemotherapy|January 13, 2010
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatmentH G M Niesters, F Zoulim, C Pichoud, et al.International Journal of Cancer|March 23, 2000
Environmental and genetic determinants of aflatoxin-albumin adducts in the GambiaC P Wild, F Yin, P C Turner, et al.Gastroenterology|August 1, 1991
Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitisX Causse, H Godinot, M Chevallier, et al.Pageof 14